Drug Profile
Research programme: I-kappa B kinase inhibitors - Millennium/sanofi-aventis
Alternative Names: MLN 120B; PS 1145Latest Information Update: 19 Mar 2012
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Millennium; Sanofi; sanofi-aventis
- Class
- Mechanism of Action I-kappa B kinase inhibitors; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Chronic obstructive pulmonary disease; Inflammation; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 18 Mar 2009 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 18 Mar 2009 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 18 Mar 2009 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (unspecified route)